Patients with stable angina or unstable angina
Conditions
Interventions
Sponsors
Kanagawa PTCA Conference
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Among subjects registered for the TRUTH Study, patients (FAS subjects) available for baseline and follow-up measurement of coronary artery plaque using VH-IVUS gave consent to participate in this research
Exclusion criteria
Exclusion criteria: 1)Patients meeting the contraindications or relative contraindications for pitavastatin and pravastatin 2)Patients with hepatic disorder or with AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limits of normal 3)Patients with renal dysfunction(serum creatinine 2.0mg/dL or higher) 4)Patients with a history of severe muscular disorder or with CK(CPK) greater than 2.5 times of the upper limit of normal 5)Patients with acute myocardial infarction occurred within 24 hours 6)Patients having failed to PCI 7)Patients with cerebrovascular accident occurred within 1 month 8)Patients with concurrent or a history of malignant tumor within 5 years prior to start of the investigationak drug 9)Patients receiving LDL apheresis 10)Patients with homozygous familial hypercholesterolemia 11)Patients requiring the following prohibited concomitant drugs 12)Drug abusers 13)Patients participating in other studies 14)Patients ineligible for the study determined by doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in component of coronary artery plaque measured by VH-IVUS | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Vessel volume, Lumen volume, Plaque volume 2)Cardiovascular composite events (cardiovascular death, nonfatal myocardial infarction, nonfatal cerebral infarction, unstable angina, revascularization except target lesion revascularization) 3)change of serum lipid (TC, LDL-C, TG, HDL-C) 4)others marker (hs-CRP) | — |
Countries
Japan
Outcome results
None listed